Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $86.7 million.

  • Nurix Therapeutics' Shares Outstanding (Weighted Average) rose 2912.18% to $86.7 million in Q4 2025 from the same period last year, while for Nov 2025 it was $86.7 million, marking a year-over-year increase of 2912.18%. This contributed to the annual value of $86.7 million for FY2025, which is 2912.18% up from last year.
  • Nurix Therapeutics' Shares Outstanding (Weighted Average) amounted to $86.7 million in Q4 2025, which was up 2912.18% from $84.2 million recorded in Q3 2025.
  • Over the past 5 years, Nurix Therapeutics' Shares Outstanding (Weighted Average) peaked at $86.7 million during Q4 2025, and registered a low of $38.8 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $54.3 million (2023), whereas its average is $58.6 million.
  • Per our database at Business Quant, Nurix Therapeutics' Shares Outstanding (Weighted Average) surged by 107379.33% in 2021 and then surged by 161.98% in 2024.
  • Over the past 5 years, Nurix Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $42.9 million in 2021, then increased by 13.32% to $48.6 million in 2022, then increased by 11.79% to $54.3 million in 2023, then grew by 23.52% to $67.1 million in 2024, then grew by 29.12% to $86.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $86.7 million in Q4 2025, compared to $84.2 million in Q3 2025 and $83.9 million in Q2 2025.